Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Abstract
Increased generation of reactive oxygen species (ROS) and an altered redox status have long been observed in cancer cells, and recent studies suggest that this biochemical property of cancer cells can be exploited for therapeutic benefits. Cancer cells in advanced stage tumours frequently exhibit multiple genetic alterations and high oxidative stress, suggesting that it might be possible to preferentially eliminate these cells by pharmacological ROS insults. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. We argue that modulating the unique redox regulatory mechanisms of cancer cells might be an effective strategy to eliminate these cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, available data suggest that MGF-driven restoration of redox homeostasis represents a central mechanistic axis of its antitumor activity, rather than merely a downstream branch of apoptosis (84,85).”
From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [84]
In the citing paper
“Activation of oncogenes, aberrant metabolism, mitochondrial dysfunction, and loss of the tumor suppressor p53 can all promote increased ROS accumulation in cancer cells 69.”
From Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes (2010) · cites this paper as [69]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379 · cited 1×
“It has been observed that a small subpopulation of primary cancer cells expressing stem-cell markers was resistant to certain chemotherapeutic agents and radiatio”
BackgroundSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587 · cited 1×
“A moderate increase in ROS can promote cell proliferation and differentiatio”
BackgroundFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“By exploiting the genetic differences between normal cells and cancer cells, several molecular-targeted drugs, such as imatinib (Gleevec; Novartis) and trastuzumab (Herceptin; Genentech/Roche), show promising therapeutic activity and few toxic side effect”
BackgroundCancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429 · cited 1×
“Redox status in cancer stem cells Recurrence of cancer after chemotherapy or radiotherapy is initiated by a subpopulation of residual malignant cells that are highly resistant to treatment and which are believed to be cancer-initiating cells or cancer stem cell”
Background(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555 · cited 1×
“Recent studies showed that normal haemopoietic stem cells and normal mammary epithelial stem cells maintained ROS at lower levels than their mature progeny to prevent cellular differentiation and maintain long-term self-renewa”
BackgroundBjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272 · cited 1×
“This is consistent with the high incidence of p53 mutation or loss of p53 function in over 50% of human cancer”
Background
Research works printed but not linked: 1
- Kim, G. J., Chandrasekaran, K. & Morgan, W. F. Mitochondrial dysfunction, persistently elevated levels of reactive oxygen species and radiation-induced genomic instability: a review. Mutagenesis 21, 361–367 (2006). · DOI · Paper page
Cited by
Items 701–800 of 1,014
Increased xCT Expression Correlates With Tumor Invasion and Outcome in Patients With Glioblastomas
Takeuchi, S., Wada, K., Toyooka, T., Shinomiya, N., Shimazaki, H., Nakanishi, K., Nagatani, K., Otani, N., Osada, H., Uozumi, Y., et al. (2013) · Neurosurgery · doi:10.1227/neu.0b013e318276b2de · Cited by 103
Redox Signaling Regulated by Cysteine Persulfide and Protein Polysulfidation
Kasamatsu, S., Nishimura, A., Morita, M., Matsunaga, T., Hamid, H. A., & Akaike, T. (2016) · Molecules · doi:10.3390/molecules21121721 · Cited by 112
Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology
Choudhury, H., Pandey, M., Yin, T. H., Kaur, T., Jia, G. W., Tan, S. Q. L., Weijie, H., Yang, E. K. S., Keat, C. G., Bhattamisra, S. K., et al. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.04.005 · Cited by 108
Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells
Lee, S., Hallis, S. P., Jung, K.-A., Ryu, D., & Kwak, M.-K. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101210 · Cited by 104
Orthogonal Activation of RNA‐Cleaving DNAzymes in Live Cells by Reactive Oxygen Species
Xiao, L., Gu, C., & Xiang, Y. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201908105 · Cited by 112
In vitro anticancer activity of fucoidan extracted from Sargassum cinereum against Caco-2 cells
Narayani, S. S., Saravanan, S., Jaganathan, R., Ramasamy, M. S., & Chitra, J. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.07.127 · Cited by 110
Driehuis, E., Spelier, S., Beltrán Hernández, I., de Bree, R., M. Willems, S., Clevers, H., & Oliveira, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111880 · Cited by 104
Loenhout, J. V., Peeters, M., Bogaerts, A., Smits, E., & Deben, C. (2020) · Antioxidants · doi:10.3390/antiox9121188 · Cited by 114
“Another antioxidant is the thioredoxin/thioredoxin reductase (Trx/TrxR) system, which is shown to be upregulated in cancer cells and is correlated with cancer aggressiveness and drug resistance [30].”
BackgroundLiving on the Edge: ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target
Brandl, N., Seitz, R., Sendtner, N., Müller, M., & Gülow, K. (2025) · Antioxidants · doi:10.3390/antiox14081002 · Cited by 129
“These findings underscore the role of ROS as active modulators of tumor-promoting signaling, rather than passive byproducts of dysregulated metabolism [76].”
Dozio, E., Ruscica, M., Passafaro, L., Dogliotti, G., Steffani, L., Pagani, A., Demartini, G., Esposti, D., FRASCHINI, F., & Magni, P. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.05.009 · Cited by 109
“On the other hand, pro-oxidant compounds, by increasing oxidative stress to a cytotoxic level, may also be useful in promoting cancer cell death (Trachootham et al., 2009).”
BackgroundInfluentialHielscher, A., & Gerecht, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.09.015 · Cited by 103
“Indeed, while tumors utilize ROS to their growth advantage, very high levels of ROS are cytotoxic and result in tumor cell death [80].”
BackgroundSerini, S., Fasano, E., Piccioni, E., Cittadini, A. R. M., & Calviello, G. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200314p · Cited by 121
Marzenell, P., Hagen, H., Sellner, L., Zenz, T., Grinyte, R., Pavlov, V. V., Daum, S., & Mokhir, A. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400754c · Cited by 115
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia
Gregory, M. A., D’Alessandro, A., Alvarez-Calderon, F., Kim, J., Nemkov, T., Adane, B., Rozhok, A. I., Kumar, A., Kumar, V., Pollyea, D. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603876113 · Cited by 106
Jutooru, I., Guthrie, A. S., Chadalapaka, G., Pathi, S. S., Kim, K., Burghardt, R. C., Jin, U.-H., & Safe, S. H. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01602-13 · Cited by 109
“intracellular redox systems result in cell death (3).”
BackgroundVilema-Enríquez, G., Arroyo, A., Grijalva, M., Amador-Zafra, R. I., & Camacho, J. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1908164 · Cited by 118
“As cancer cells generate high concentrations of ROS and are under increased intrinsic oxidative stress, they might be more vulnerable to further oxidative insults produced by ROS-generating agents [114].”
BackgroundLi, Y., Huan, K., Deng, D., Tang, L., Wang, J., & Luo, L. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b19126 · Cited by 109
Dong, L., Jameson, V. J. A., Tilly, D., Procházka, L., Rohlena, J., Vališ, K., Truksa, J., Zobalová, R., Mahdavian, E., Kľučková, K., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.02.032 · Cited by 111
de Castro, S. L., Emery, F. D. S., & Júnior, E. N. D. S. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.07.057 · Cited by 106
Whitaker, H. C., Patel, D., Howat, W., Warren, A. Y., Kay, J. D., Sangan, T., Marioni, J. C., Mitchell, J., Aldridge, S., Luxton, H. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.396 · Cited by 115
“ROS regulation is a novel mechanism leading to anti-androgen resistance which could be exploited for as therapeutic targets for small-molecule inhibitors or radiotherapy (Trachootham et al, 2009; Zhang et al, 2009).”
BackgroundDesign, Synthesis, and Phenotypic Profiling of Pyrano‐Furo‐Pyridone Pseudo Natural Products
Christoforow, A., Wilke, J., Binici, A., Pahl, A., Ostermann, C., Sievers, S., & Waldmann, H. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201907853 · Cited by 117
Metabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 113
Near‐Infrared Light‐Triggered Chlorine Radical (.Cl) Stress for Cancer Therapy
Song, R., Wang, H., Zhang, M., Liu, Y., Meng, X., Zhai, S., Wang, C., Gong, T., Wu, Y., Jiang, X., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202007434 · Cited by 106
Chen, Y., Huang, X.-C., Luo, Y.-L., Chang, Y.-C., Hsieh, Y., & Hsu, H. (2013) · Science and Technology of Advanced Materials · doi:10.1088/1468-6996/14/4/044407 · Cited by 114
“For example, larger particles are often necessary for optical applications, whereas smaller particles ( 50 nm) are desirable for cellular uptake [9].”
BackgroundInvolvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells
Rakshit, S., Mandal, L., Pal, B. C., Bagchi, J., Biswas, N., Chaudhuri, J., Chowdhury, A. A., Manna, A., Chaudhuri, U., Konar, A., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.013 · Cited by 113
Khan, M. A., Gahlot, S., & Majumdar, S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0141 · Cited by 106
“Research has established that one common biochemical change in malignant cells is the increased production of ROS due to high metabolism (21).”
BackgroundBeekman, A. T. F., van Limbeek, J., Deeg, D. J. H., Wouters, L. F., & van Tilburg, W. (1994) · PubMed · Cited by 142
Recent Developments of Inorganic Nanosensitizers for Sonodynamic Therapy
He, Z., Du, J., Miao, Y., & Li, Y. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300234 · Cited by 105
The paradigm of mutant p53-expressing cancer stem cells and drug resistance
Shetzer, Y., Solomon, H., Koifman, G., Molchadsky, A., Horesh, S., & Rotter, V. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu073 · Cited by 110
“ROS are found at high levels in many cancer cells, contributing to the vicious cycle of aggravating damage to the DNA and other parts of the cell (209).”
BackgroundZhang, J., Li, Y., Duan, D., Yao, J., Gao, K., & Fang, J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.004 · Cited by 109
Namani, A., Rahaman, M. M., Chen, M., & Tang, X. (2018) · BMC Cancer · doi:10.1186/s12885-017-3907-z · Cited by 108
Peng, J., Yang, Q., Shi, K., Xiao, Y., Wei, X., & Qian, Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.007 · Cited by 104
Tan, C., Wu, S., Lai, S., Wang, M., Chen, Y. X., Zhou, L., Zhu, Y., Lian, W., Peng, W., Ji, L., et al. (2011) · Dalton Transactions · doi:10.1039/c1dt10084j · Cited by 117
The Hallmarks of Cancer from a Redox Perspective
Hornsveld, M., & Dansen, T. B. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6580 · Cited by 115
“Targeting general redox homeostasis by anti-or pro-oxidant treat-ment can have both negative and positive effects on tumor biology and has already been tested in multiple ways (81, 83, 231, 255).”
Emmink, B. L., Laoukili, J., Kipp, A. P., Koster, J., Govaert, K. M., Fatrai, S., Verheem, A., Steller, E. J. A., Brigelius-Flohé, R., Jimenez, C. R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1645 · Cited by 104
“However, excessive ROS generation can also lead to cell cycle arrest, senescence and programmed cell death (1, 8, 9).”
BackgroundSamoylenko, A., Hossain, J. A., Mennerich, D., Kellokumpu, S., Hiltunen, J. K., & Kietzmann, T. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4662 · Cited by 100
“Therapeutic strategies exploiting the role of ROS both as an inducer and an inhibitor of tumorigenesis are being developed (294, 351).”
Endogenous Stimuli-responsive Nanocarriers for Drug Delivery
Chen, H., Liu, D., & Guo, Z. (2016) · Chemistry Letters · doi:10.1246/cl.151176 · Cited by 109
Tian, M., Li, J., Zhang, S., Guo, L., He, X., Kong, D., Zhang, H., & Liu, Z. (2017) · Chemical Communications · doi:10.1039/c7cc08270c · Cited by 104
The impact of oncogenic RAS on redox balance and implications for cancer development
Lim, J. K. M., & Leprivier, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2192-y · Cited by 115
Enzyme catalysis powered micro/nanomotors for biomedical applications
Mathesh, M., Sun, J., & Wilson, D. A. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01245a · Cited by 108
Lei, H., Wang, X., Bai, S., Gong, F., Yang, N., Gong, Y., Hou, L., Cao, M., Liu, Z., & Cheng, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c14647 · Cited by 104
Role of SLC7A11/xCT in Ovarian Cancer
Fantone, S., Piani, F., Olivieri, F., Rippo, M. R., Sirico, A., Simone, N. D., Marzioni, D., & Tossetta, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010587 · Cited by 110
Mailloux, R. J., Adjeitey, C. N.-K., & Harper, M.-E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013289 · Cited by 99
“. Although cancer cells invoke numerous strategies to nullify toxins, tight control over ROS levels represents a major adaptive response”
BackgroundUCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress
Pons, D. G., Nadal‐Serrano, M., Torrens‐Mas, M., Valle, A., Oliver, J., & Roca, P. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.032 · Cited by 107
Chang, H., Wang, X., Shiu, K.-K., Zhu, Y., Wang, J., Li, Q., Chen, B., & Jiang, H. (2012) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2012.10.001 · Cited by 103
“), kkshiu@hkbu.edu.hk l., Biosensors and Bioelectro high oxidative stress existing in carcinomatous cell (Szatrowski and Nathan, 1991; Toyokuni et al., 1995; Lau et al., 2008; Trachootham et al., 2009; Visconti and Grieco, 2009).”
BackgroundInfluentialLinking vitamin B1 with cancer cell metabolism
Zastre, J. A., Sweet, R. L., Hanberry, B. S., & Ye, S. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-16 · Cited by 109
Escaping Death: Mitochondrial Redox Homeostasis in Cancer Cells
Ciccarese, F., & Ciminale, V. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00117 · Cited by 108
“Thus, modulation of ROS levels is a promising anticancer strategy (45).”
BackgroundPhytochemicals as potent modulators of autophagy for cancer therapy
Moosavi, M. A., Haghi, A., Rahmati, M., Taniguchi, H., Mocan, A., Echeverría, J., Gupta, V. K., Tzvetkov, N. T., & Atanasov, A. G. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.030 · Cited by 108
Oxidative stress in female cancers
Calaf, G. M., Urzúa, U., Termini, L., & Aguayo, F. (2018) · Oncotarget · doi:10.18632/oncotarget.25323 · Cited by 117
“It is known that levels of ROS are often up regulated in cancer cells, and their role in promoting certain signaling cascades is likely one reason that this adaptation is advantageous [61].”
BackgroundMixed-ligand Cu(II) hydrazone complexes designed to enhance anticancer activity
Mo, Q., Deng, J., Liu, Y., Huang, G., Li, Z., Yu, P., Gou, Y., & Yang, F. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.022 · Cited by 105
Base excision repair regulates PD-L1 expression in cancer cells
Permata, T. B. M., Hagiwara, Y., Sato, H., Yasuhara, T., Oike, T., Gondhowiardjo, S. A., Held, K. D., Nakano, T., & Shibata, A. (2019) · Oncogene · doi:10.1038/s41388-019-0733-6 · Cited by 108
“In contrast to IR, oxidative stress induces base damage and single-strand breaks (SSBs), but does not directly induce DSBs. Reactive oxygen species (ROS) produced under oxidative stress are a major source of DNA damage, and cancer cells in particular are characterised by persistent oxidative stress and high levels of…”
BackgroundInfluentialGraphene-Based Electrochemical Biosensors for Breast Cancer Detection
Mohammadpour-Haratbar, A., Boraei, S. B. A., Zare, Y., Rhee, K. Y., & Park, S. (2023) · Biosensors · doi:10.3390/bios13010080 · Cited by 106
Addicted to secrete – novel concepts and targets in cancer therapy
Dejeans, N., Manié, S. N., Hetz, C. A., Bard, F., Hupp, T. R., Agostinis, P., Samali, A., & Chevet, É. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.12.003 · Cited by 111
Metformin: A Novel Biological Modifier of Tumor Response to Radiation Therapy
Koritzinsky, M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.06.003 · Cited by 109
“Interestingly, this effect may be exacerbated in cancer cells that are characterized by high levels of ROS and oxidative stress (56, 60, 61).”
BackgroundInfluentialShitara, K., Doi, T., Nagano, O., Imamura, C. K., Ozeki, T., Ishii, Y., Tsuchihashi, K., Takahashi, S., Nakajima, T. E., Hironaka, S., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0610-8 · Cited by 115
“CSCs are also more resistant to conventional therapeutic interventions than are other cancer cells [2, 3], with one resistance mechanism being dependent on an enhanced ability of CSCs to protect themselves against reactive oxygen species (ROS) [4].”
BackgroundVaneev, A. N., Gorelkin, P. V., Garanina, A. S., Lopatukhina, H., Vodopyanov, S., Alova, A. V., Ryabaya, O. O., Akasov, R., Zhang, Y., Novák, P., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01256 · Cited by 108
Arambula, J. F., McCall, R., Sidoran, K. J., Magda, D. J., Mitchell, N. A., Bielawski, C. W., Lynch, V. M., Sessler, J. L., & Arumugam, K. (2015) · Chemical Science · doi:10.1039/c5sc03519h · Cited by 102
Narayanaswamy, N., Narra, S., Nair, R. R., Saini, D. K., Kondaiah, P., & Govindaraju, T. (2016) · Chemical Science · doi:10.1039/c5sc03488d · Cited by 101
Zhang, Z., Guo, M. L., Zhao, S., Shao, J., & Zheng, S. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.10.498 · Cited by 104
Zhang, Y., Liang, Y., & He, C. (2017) · Chinese Medicine · doi:10.1186/s13020-017-0140-2 · Cited by 110
“Since tumors frequently exhibit high levels of oxidative stress [71], a general disturbance of redox balance in cancer cells by HCD herbal compounds may contribute to their multifarious anticancer effects.”
BackgroundPi, W., Wu, L., Lu, J., Lin, X., Huang, X., Wang, Z., Yuan, Z., Qiu, H., Zhang, J., Lei, H., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.06.018 · Cited by 135
“CDT induces apoptosis relying on production reactive oxygen species (ROS) such as hydroxyl radicals (⋅OH) and superoxide anions (⋅O2− ) in the TME [12].”
BackgroundCuproptosis: mechanisms and nanotherapeutic strategies in cancer and beyond
Mao, L., Lu, J., Wen, X., Song, Z., Sun, C., Zhao, Y., Huang, F., Chen, S., Jiang, D., Che, W., et al. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00083a · Cited by 110
Kaushik, N. K., Kaushik, N., Park, D., & Choi, E. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103349 · Cited by 108
“Some researchers claim that ROS induced by anticancer drugs produce a shift in cellular antioxidant machinery [18,19] and in mitochondrial membrane potential, which is related to induction of programmed”
BackgroundMolecular mechanisms of mTOR regulation by stress
Heberle, A. M., Prentzell, M. T., van Eunen, K., Bakker, B. M., Grellscheid, S. N., & Thedieck, K. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.970489 · Cited by 97
“Of note, ROS formation in cancer cells has been often linked with an induction of oncogenic signaling (Trachootham et al., 2009), for example of the mitogen activated protein kinase (MAPK) and PTEN/Akt pathways (Goo et al., 2012; Kodama et al., 2013; Vafa et al., 2002; Weyemi et al., 2012).”
BackgroundLiu, J. M., Pan, F., Li, L., Liu, Q. R., Chen, Y., Xiong, X., Cheng, K., Yu, S., Shi, Z., Yu, A. C., et al. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.042 · Cited by 102
Joh, H. M., Choi, J. Y., Kim, S. J., Chung, T. H., & Kang, T. (2014) · Scientific Reports · doi:10.1038/srep06638 · Cited by 101
Chapman, C. M., Sun, E. X., Roschewski, M. J., Aue, G., Farooqui, M., Stennett, L. S., Gibellini, F., Arthur, D. C., Pérez‐Galán, P., & Wiestner, A. U. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2113 · Cited by 106
“Pharmacologic induction of ROS is increasingly recognized as a therapeutic principle to selectively kill transformed cells (39, 40).”
Ding, Y., Wang, H., Niu, J., Luo, M., Gou, Y., Miao, L., Zou, Z., & Cheng, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040558 · Cited by 104
“At the same time, extensive oxidative DNA damage caused by elevated ROS may abrogate the cellular repair capacity to trigger DNA damage response (DDR), which then lead to cell cycle arrest, premature cellular senescence, or programmed cell death, therefore blocking cancer development and progression [14].”
BackgroundLi, W., Guo, Y., Zhang, C., Wu, R., Yang, Y., Gaspar, J. M., & Kong, A. T. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00413 · Cited by 109
Zhao, Q., Liu, Y., Zhong, J., Bi, Y., Liu, Y., Ren, Z., Li, X., Jia, J., Yu, M., & Yu, X. (2019) · Cell Death Discovery · doi:10.1038/s41420-019-0208-0 · Cited by 102
Wang, F., Wu, H., Fan, M., Yu, R., Zhang, Y., Liu, J., Zhou, X., Cai, Y., Huang, S., Hu, Z., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902626r · Cited by 109
Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities
Wang, M., Xiao, Y., Miao, J., Zhang, X., Liu, M., Zhu, L., Liu, H., Shen, X., Wang, J., Xie, B., et al. (2025) · Antioxidants · doi:10.3390/antiox14060735 · Cited by 129
Chu, S., Hsieh, Y., Yu, C., Lai, Y.-Y., & Chen, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101579 · Cited by 101
“Thus, cancer cells are vulnerable to damage caused by ROS because scavenging increased ROS induced by exogenous agents or drugs in cancer cells is more difficult than that in normal cells [34].”
BackgroundConrad, M., Sandin, Å., Förster, H., Seiler, A., Frijhoff, J., Dagnell, M., Bornkamm, G. W., Rådmark, O., van Huijsduijnen, R. H., Aspenström, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007909107 · Cited by 98
“There is also an altered redox status in cancer cells, which may lead to increased levels of peroxidized lipids (49).”
BackgroundKawamura, T., Kawatani, M., Muroi, M., Kondoh, Y., Futamura, Y., Aono, H., Tanaka, M., Honda, K., & Osada, H. (2016) · Scientific Reports · doi:10.1038/srep26521 · Cited by 105
der Paal, J. V., Verheyen, C., Neyts, E. C., & Bogaerts, A. (2017) · Scientific Reports · doi:10.1038/srep39526 · Cited by 110
Radiation Resistance: A Matter of Transcription Factors
Galeaz, C., Totis, C., & Bisio, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.662840 · Cited by 110
“Another advantage that leads to radioresistance in CSCs is the fact that they exhibit low ROS levels, due to an increased expression of ROS scavenging molecules, such as GSH, SOD, Catalase, and Thioredoxin (45).”
BackgroundZhu, L., Luo, M., Zhang, Y., Fang, F., Li, M., An, F., Zhao, D., & Zhang, J. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214875 · Cited by 115
Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds
Chen, G., Wang, F., Trachootham, D., & Huang, P. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.08.001 · Cited by 109
“Indeed, several ROSmodulating agents seem to exhibit promising therapeutic activity in preclinical and clinical studies (Trachootham et al., 2009).”
InfluentialSelf-citationGuzzo, G., Sciacovelli, M., Bernardi, P., & Rasola, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2472 · Cited by 105
“It is reasonable to envision that redox conditions might fluctuate during the complex process of tumor progression, and that a shift towards higher intracellular ROS levels may become extremely important at advanced stages of tumor growth, when increasing mutagenicity is essential to shape malignant properties of neop…”
InfluentialHuang, Y., Zhu, D., Chen, X., Chen, Q.-K., Luo, Z., Chang-chun, L., Wang, G., Zhang, W., & Liao, N.-Z. (2017) · Oncotarget · doi:10.18632/oncotarget.16828 · Cited by 102
“While cancer cells may potentially benefit from oxidative stress because of the increased rate of mutations [23, 24], cancer cells have a higher basal level of oxidative stress than non-malignant cells, making them vulnerable to the acute induction of oxidative stress [24, 25].”
BackgroundThe mitochondrial permeability transition pore and its adaptive responses in tumor cells
Rasola, A., & Bernardi, P. (2014) · Cell Calcium · doi:10.1016/j.ceca.2014.10.003 · Cited by 91
Li, L., Yang, J., Wei, J., Jiang, C., Liu, Z., Yang, B. J., Zhao, B., & Song, W. (2022) · Light Science & Applications · doi:10.1038/s41377-022-00968-5 · Cited by 101
Recent advances in drug delivery systems for targeting brain tumors
Zhao, Y., Yue, P., Peng, Y., Sun, Y., Chen, X., Zhao, Z., & Han, B.-J. (2023) · Drug Delivery · doi:10.1080/10717544.2022.2154409 · Cited by 105
“When the content exceeds the tolerance value of cells, it will induce cell necrosis and apoptosis (Trachootham et al., 2009).”
BackgroundCao, S., Long, Y., Xiao, S., Deng, Y., Ma, L., Adeli, M., Qiu, L., Cheng, C., & Zhao, C. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00087g · Cited by 103
Luca, A. D., Sanna, F., Sallese, M., Ruggiero, C., Grossi, M., Sacchetta, P., Rossi, C., Laurenzi, V. D., Ilio, C. D., & Favaloro, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010171107 · Cited by 106
“C cells show increased reactive oxygen species (ROS) generation, whichmight promote cell proliferation and which, in many cases, might be coupled to redox adaptation promoting cell survival and drug resistance (1).”
BackgroundYoon, S., Choi, S., Sim, B., Kim, J.-S., Mun, S.-E., Jeong, P., Yang, H.-J., Lee, Y., Park, Y., Song, B., et al. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.113.113480 · Cited by 106
He, G., He, G., Zhou, R., Pi, Z., Zhu, T., Jiang, L., & Xie, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.100 · Cited by 104
Cao, L., Chen, X., Xiao, X., Ma, Q., & Li, W. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3559 · Cited by 107
Pallichankandy, S., Rahman, A. U., Thayyullathil, F., & Galadari, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.10.404 · Cited by 102
Dejeans, N., Glorieux, C., Guénin, S., Beck, R., Sid, B., Rousseau, R., Bisig, B., Delvenne, P., Calderón, P. B., & Verrax, J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.12.019 · Cited by 103
“Thus, many types of cancer cells exhibit increased intracellular levels of reactive oxygen species (ROS), which can promote a high level of cell proliferation and an increased adaptation capacity [1].”
BackgroundRole of free radicals in human inflammatory diseases
Biswas, S., Das, R., & Banerjee, E. R. (2017) · AIMS Biophysics · doi:10.3934/biophy.2017.4.596 · Cited by 105
“Cellular DNA can be damaged by reactive oxygen species lead to genetic changes and as a result, uncontrolled regulation of oncogenes and tumour suppressor genes finally contributes to carcinogenesis [171,172,173].”
Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway
Lü, Y., Sun, Y., Zhu, J., Yu, L., Jiang, X., Zhang, J., Dong, X., Ma, B., & Zhang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0031-6 · Cited by 101
Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer
Hatem, E., Azzi, S., Banna, N. E., He, T., Heneman-Masurel, A., Vernis, L., Baïlle, D., Masson, V., Dingli, F., Loew, D., et al. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy149 · Cited by 105
Cascade of reactive oxygen species generation by polyprodrug for combinational photodynamic therapy
Feng, Z., Guo, J., Liu, X., Song, H., Zhang, C., Huang, P., Dong, A., Kong, D., & Wang, W. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120210 · Cited by 99
Self-citationChien, C.-H., Hsueh, W., Chuang, J., & Chang, K. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00717-7 · Cited by 108
Cold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunity
Faramarzi, F., Zafari, P., Alimohammadi, M., Moonesi, M., Rafiei, A., & Bekeschus, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9916796 · Cited by 105
“In some studies, enhanced intracellular ROS in cancer cells makes them more susceptible to cell death induced by extracellular ROS [64, 65].”
BackgroundActivatable Probes for Ratiometric Imaging of Endogenous Biomarkers In Vivo
Fu, Q., Yang, X. P., Wang, M., Zhu, K., Wang, Y., & Song, J. (2024) · ACS Nano · doi:10.1021/acsnano.3c10659 · Cited by 104
Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful?
Takaki, A., & Yamamoto, K. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.968 · Cited by 105
Wang, H., Bouzakoura, S., de Mey, S., Jiang, H., Ka, L. L., Dufait, I., Corbet, C., Verovski, V. N., Gevaert, T., Féron, O., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16113 · Cited by 108
“Briefly, ROS may display both pro- and anti-tumor properties, and on the top we could expect both proand anti-inflammatory effects from AF, considering the history of its use as an anti-arthritic drug [33].”
Background
Metadata
- Authors
- Trachootham, D., Alexandre, J., & Huang, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Huang, Peng
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-05-29
- Volume
- 8
- Issue
- 7
- Pages
- 579-591
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1972779889
- Cited by
- 5,452
- References
- 163
- Citations by year
- 2026: 322 · 2025: 332 · 2024: 340 · 2023: 372 · 2022: 421 · 2021: 462 · 2020: 444 · 2019: 454 · 2018: 393 · 2017: 404 · 2016: 341 · 2015: 289 · 2014: 282 · 2013: 204 · 2012: 158
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA085563, R01CA109041, CA109041, R01CA085563, R01CA100428, CA100428)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer and biochemical research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- reactive oxygen species, oxidative stress, redox modulation, cancer cells, drug resistance, antioxidant capacity, anticancer agents, genomic instability
- MeSH terms
- Adaptation, Physiological, Animals, Glutathione, Humans, Neoplasms, Oxidation-Reduction, Neoplastic Stem Cells, Reactive Oxygen Species, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.